LncRNA-mediated organization of oncogenic chromatin state is a targetable vulnerability in leukemia
Vu, L. P.; Jin, Z.; Ma, B.; Chan, K.; Lin, D.; Ghosh, D.; Louwagie, A.; Saville, L.; Chandra, J. L.; Liu, Y.; Liu, Z.; Escano, L.; Miko, S. S.; Cheng, S. W. G.; Stricker, P.; Edin, G.; Wong, F.; Dong, K.; Hoang, Q. A.; Bui, Q. T. T.; Schurer, A.; Do, K.; Chou, T.; Oakes, C.; Basha, G.; Sauvageau, M.; Hussein, S. M. I.; Morin, G.; Perna, F.; Kuchenbauer, F.; Kharas, K. G.; Karsan, A.; Cullis, P. R.
Show abstract
Long non-coding RNAs (lncRNAs) are increasingly recognized as critical regulators of gene expression underlying various cellular functions, however, the functional and mechanistic contributions of most lncRNAs to tumorigenesis remain poorly defined, and targeting of lncRNAs is challenging with conventional therapeutic approaches. Here, we uncover human PAN3-AS1 and its murine ortholog Lnc35682, previously uncharacterized lncRNAs embedded within a conserved syntenic genomic locus, as highly expressed in acute myeloid leukemia (AML). Using genetic mouse models, human cell lines and primary patient samples, we show that PAN3-AS1 is essential for leukemia maintenance but dispensable for normal hematopoiesis. Mechanistically, we find that elevated PAN3-AS1 influences chromatin accessibility, thus promoting leukemia gene expression programs. This is mediated, at least in part, by PAN3-AS1s association with the nuclear lamina through a defined functional region that is required for its leukemogenic function. We further characterize a feed-forward regulatory circuit between PAN3-AS1 and its neighboring gene FLT3 that directly links the aberrant lncRNA functions to the FLT3-mutant AML subtype. To therapeutically exploit the regulatory node, we engineer a myeloid leukemia-preferentially targeted lipid nanoparticle (LNP) formulation and demonstrate effective delivery of siRNAs against endogenous targets into leukemia cells in experimental animals. LNP-siPAN3-AS1 alone or in combination with a clinically used FLT3 inhibitor, Gilteritinib, reduces leukemia burden and significantly delay leukemogenesis in vivo. Overall, our study uncovers a therapeutic vulnerable lncRNA-centric circuitry and provides compelling preclinical evidence for the development and application of a novel RNA targeting-LNP based therapy for treatment of myeloid leukemia. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=200 SRC="FIGDIR/small/744058v1_ufig1.gif" ALT="Figure 1"> View larger version (52K): org.highwire.dtl.DTLVardef@b1d833org.highwire.dtl.DTLVardef@1e8fda6org.highwire.dtl.DTLVardef@164d39corg.highwire.dtl.DTLVardef@80c747_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- FASN Inactivation-induced Progranulin (GRN) Expression Promotes Lysosome-dependent Cell Death to Suppress Leukemogenesis 94%
- Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth 93%
- Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells 93%
Similar papers in this journal
- Exploring Mechanisms of Action in Combinatorial Therapies through Solubility Alterations: Advancing AML Treatment 94%
- Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemia 93%
- Adrenomedullin-CALCRL Axis Controls Relapse-Initiating Drug Tolerant Acute Myeloid Leukemia Cells 93%
Similar papers in this journal
- Unraveling the molecular mechanisms underlying spontaneous multipolar mitosis through CIN-seq 90%
- ProT-Diff: A Modularized and Efficient Approach to De Novo Generation of Antimicrobial Peptide Sequences through Integration of Protein Language Model and Diffusion Model 89%
- Cancer-like fragmentomic characteristics of somatic variants in cell-free DNA 89%
Similar papers in this journal
- Loss Of Kat2a Enhances Transcriptional Noise And Depletes Acute Myeloid Leukemia Stem-Like Cells 94%
- Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia 94%
- Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia 92%
Similar papers in this journal
- Patient-tailored design of AML cell subpopulation-selective drug combinations 93%
- TCF3::HLF Orchestrates an Enhancer-Promoter Network with Activation of MEF2C to Promote Immature HSC gene Expression in Leukemia 92%
- TP53-mutant AML with ribosomal gene loss exhibits impaired protein translation and sensitivity to HSP90 inhibition 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.